Hartman Institute for Therapeutic Organ Regeneration

A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization.

TitleA catalytic role for proangiogenic marrow-derived cells in tumor neovascularization.
Publication TypeJournal Article
Year of Publication2008
AuthorsSeandel M, Butler J, Lyden D, Rafii S
JournalCancer Cell
Volume13
Issue3
Pagination181-3
Date Published2008 Mar
ISSN1878-3686
KeywordsAngiogenic Proteins, Animals, Bone Marrow Cells, Bone Marrow Transplantation, Cell Hypoxia, Cell Movement, Endothelial Cells, Glioblastoma, Hypoxia-Inducible Factor 1, alpha Subunit, Matrix Metalloproteinase 9, Mice, Mice, Knockout, Monocytes, Myeloid Cells, Neoplasm Invasiveness, Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Stem Cells, Time Factors
Abstract

<p>Small numbers of proangiogenic bone marrow-derived cells (BMDCs) can play pivotal roles in tumor progression. In this issue of Cancer Cell, two papers, utilizing different tumor angiogenesis models, both find that activated MMP-9 delivered by BMDCs modulates neovessel remodeling, thereby promoting tumor growth. The changes in microvascular anatomy induced by MMP-9-expressing BMDCs are strikingly different between the preirradiated tumor vascular bed model employed by Ahn and Brown and the invasive glioblastoma model utilized by Du et al., likely mirroring the complexity of the real tumor microenvironment and the intricacy of roles of different BMDC populations in mediating tumor neoangiogenesis.</p>

DOI10.1016/j.ccr.2008.02.016
Alternate JournalCancer Cell
PubMed ID18328420
PubMed Central IDPMC2951026
Grant ListR01 HL061849-04 / HL / NHLBI NIH HHS / United States
R01 HL097797-03 / HL / NHLBI NIH HHS / United States
P50 HL084936-010003 / HL / NHLBI NIH HHS / United States
R01 HL097797-01 / HL / NHLBI NIH HHS / United States
R01 HL058707-03 / HL / NHLBI NIH HHS / United States
R01 HL061849-03S1 / HL / NHLBI NIH HHS / United States
R01 HL075234 / HL / NHLBI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
P01 HL067839-040004 / HL / NHLBI NIH HHS / United States
R01 HL075234-04 / HL / NHLBI NIH HHS / United States
P01 HL067839-020004 / HL / NHLBI NIH HHS / United States
P50 HL084936 / HL / NHLBI NIH HHS / United States
R01 HL058707-04 / HL / NHLBI NIH HHS / United States
P50 HL084936-030003 / HL / NHLBI NIH HHS / United States
P01 HL067839 / HL / NHLBI NIH HHS / United States
R01 HL075234-03 / HL / NHLBI NIH HHS / United States
R01 HL097797-02 / HL / NHLBI NIH HHS / United States
R01 HL097797 / HL / NHLBI NIH HHS / United States
P50 HL084936-020003 / HL / NHLBI NIH HHS / United States
R01 HL061849-03 / HL / NHLBI NIH HHS / United States
R01 HL061849 / HL / NHLBI NIH HHS / United States
R01 HL075234-02 / HL / NHLBI NIH HHS / United States
R01 HL061849-05 / HL / NHLBI NIH HHS / United States
P01 HL067839-050004 / HL / NHLBI NIH HHS / United States
P01 HL067839-030004 / HL / NHLBI NIH HHS / United States
P50 HL084936-040003 / HL / NHLBI NIH HHS / United States
P01 HL067839-010004 / HL / NHLBI NIH HHS / United States
R01 HL075234-01 / HL / NHLBI NIH HHS / United States
R01 HL061849-02 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065